The MFDS, which was active in disclosing information on COVID-19 vaccine screening, is suddenly not disclosing any information on the Novavax vaccine. There was no news of the expert advisory group, and 40 days have already passed the promised screening period. Some analysts say that this is because it is difficult for the MFDS to predict the timing of approval with "quality" data different from overseas. The Novavax vaccine was reviewed by the MFDS in November. It is the fifth COVID-19 vaccine to be officially reviewed.

The previously approved vaccines of AstraZeneca, Pfizer, Janssen, and Moderna were approved 40 days after the screening. Considering the urgency of infectious diseases, the MFDS has est